Abstract: The disclosure is directed to an interactive packaging system for monitoring the usage of personal hygiene products, personal hygiene product packages, and restroom facilities. The interactive packaging system may include a plurality of usage monitoring devices each configured to detect physical stimulus associated with the usage of the product, package or facility with which the usage monitoring device is associate, and to transmit usage messages containing information relating to the detected physical stimulus. The interactive packaging system may further include a base station configured to receive the usage messages transmitted by the plurality of usage monitoring devices and to generate sensory perceptible outputs corresponding to the information contained in the usage messages. Either the usage monitoring devices or the base station may be configured to determine whether the products, packages or facilities are used appropriately based on the detected physical stimulus.

Abstract: A cleansing wipe container includes a bottom panel, a front panel, a rear panel, a pair of side panels and a lid. The cleansing wipe container may be filled with a plurality of cleansing wipes that are contained in a cartridge. The cartridge and container interact such that a message is displayed on or through a panel of the container. The message is based on the cartridge of wipes and may include a type of wipe, a list of ingredients of the wipes, and/or instructions for using the wipes.

Abstract: An isolated polypeptide comprises an amino acid sequence of SEQ ID No. 1 or 2 or a variant or fragment thereof. The variant may comprise an amino acid sequence that is at least 70% or 95% identical to the amino acid sequence of SEQ ID No. 1 or 2. A fragment thereof may be a peptide comprising at least 12 contiguous amino acids of SEQ ID No. 1 or 2. The polypeptide exhibits toll-like receptor activity. The TLR has been named TLR1 4. TLR receptors recognise a range of ligands and activate a series of signalling pathways that lead to the induction of immune and inflammatory genes.

Abstract: The disclosure is directed to an interactive packaging system for monitoring the usage of personal hygiene products, personal hygiene product packages, and restroom facilities. The interactive packaging system may include a plurality of usage monitoring devices each configured to detect physical stimulus associated with the usage of the product, package or facility with which the usage monitoring device is associate, and to transmit usage messages containing information relating to the detected physical stimulus. The interactive packaging system may further include a base station configured to receive the usage messages transmitted by the plurality of usage monitoring devices and to generate sensory perceptible outputs corresponding to the information contained in the usage messages. Either the usage monitoring devices or the base station may be configured to determine whether the products, packages or facilities are used appropriately based on the detected physical stimulus.

Abstract: Systems, methods, and computer program products are provided for monitoring of financial institution business activity for the purpose of identifying suspicious activities. The embodiments herein described rely on monitoring business activities from many data repositories, some of which are exclusive to financial institution. By monitoring financial business activity for the purpose of identifying suspicious activity or behaviors, bank fraud or other criminal/wrongful activities can be mitigated or otherwise avoided. In addition, the identification of suspicious activities serves to identify the individual(s) associated with the suspicious activities and/or other information related to the individual(s), such as physical location, electronic location, telephone number and the like.

Abstract: The disclosure is directed to an interactive packaging system for monitoring the usage of personal hygiene products, personal hygiene product packages, and restroom facilities. The interactive packaging system may include a plurality of usage monitoring devices each configured to detect physical stimulus associated with the usage of the product, package or facility with which the usage monitoring device is associate, and to transmit usage messages containing information relating to the detected physical stimulus. The interactive packaging system may further include a base station configured to receive the usage messages transmitted by the plurality of usage monitoring devices and to generate sensory perceptible outputs corresponding to the information contained in the usage messages. Either the usage monitoring devices or the base station may be configured to determine whether the products, packages or facilities are used appropriately based on the detected physical stimulus.

Abstract: A cleaning wipes container having one or more panels and a lid that covers an opening. The opening provides access to an interior storage space defined by the one or more panels. The interior storage space is configured to receive a wipes cartridge. The container also has a viewing area on at least a portion of one panel. The viewing area provides a target surface to join a transferable label. The transferable label includes indicia that relate to a characteristic of a type of cleaning wipes in the wipes cartridge. The indicia are viewable from outside the container.

Abstract: Techniques for enabling broadband data rates at mobile terminals in a beyond-line-of-sight communication system are disclosed. Forward link time-diversity transmission methods and a time-diversity transmitter based upon blockage characteristics are provided. The transmitter optionally supports selective time-diversity and can operate at Ku-band or higher frequencies. A forward link time-diversity receiver and methods for receiving a forward link time-diversity signal are also disclosed. The forward link time-diversity receiver optionally provides low-jitter or low-delay characteristics. A return link transmitter and return link transmit methods which avoid blockages are also disclosed. The return link transmitter can include a signal presence detector and blockage prediction filter.

Abstract: The disclosure is directed to an interactive packaging system for monitoring the usage of personal hygiene products, personal hygiene product packages, and restroom facilities. The interactive packaging system may include a plurality of usage monitoring devices each configured to detect physical stimulus associated with the usage of the product, package or facility with which the usage monitoring device is associate, and to transmit usage messages containing information relating to the detected physical stimulus. The interactive packaging system may further include a base station configured to receive the usage messages transmitted by the plurality of usage monitoring devices and to generate sensory perceptible outputs corresponding to the information contained in the usage messages. Either the usage monitoring devices or the base station may be configured to determine whether the products, packages or facilities are used appropriately based on the detected physical stimulus.

Abstract: Disclosed are polar quinazoline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I): in which, R1, R2, R3, R4, R5, R6, R22, R23, R24, R25, R26, R27, R28, R29, W, W1, W2, Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rm, Rn, Ro, Rp, Rq, Rr, Rs, Rt, Ru, and n can be as defined anywhere herein. In general, these compounds can be used for treating or preventing one or more diseases, disorders, conditions or symptoms mediated by LXRs.

Abstract: Disclosed are quinoxaline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I): wherein: each of L1 and L2 is, independently, a bond, —O— or —NH—; R2 is C6-C10 aryl or heteroaryl including 5-10 atoms, each of which is (i) substituted with 1 R9, and (ii) optionally further substituted with from 1-4 Re; and each of R4 and R5 is, independently (i) hydrogen; or (ii) halo; or (iii) C1-C6 alkyl or C1-C6 haloalkyl, each of which is optionally substituted with from 1-3 Ra; and R1, R3, R6, R9, Ra and Re are defined herein. In general, these compounds can be used for treating or preventing one or more diseases, disorders, conditions or symptoms mediated by LXRs.

Abstract: The present invention is directed to aryl sulfamide derivatives of formula I: or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic neuropathy, pain, and other diseases or disorders.

Abstract: A cleansing wipe container includes a bottom panel, a front panel, a rear panel, a pair of side panels and a lid. The cleansing wipe container may be filled with a plurality of cleansing wipes that are contained in a cartridge. The cartridge and container interact such that a message is displayed on or through a panel of the container. The message is based on the cartridge of wipes and may include a type of wipe, a list of ingredients of the wipes, and/or instructions for using the wipes.

Abstract: A method for the identification of novel compounds that interact and stabilize the ligand binding domain of estrogen-related receptor gamma (ERR?), a methodology for producing diffraction quality crystal structures in the presence of antagonist and agonist ligands, including Bisphenol A, and the identification of novel biologically-active compounds that have an effect on the transcriptional-activating activity of ERR? are disclosed.

Abstract: The invention relates to use of a composition comprising an inhibitor of adenylyl cyclase in the elongation of circadian rhythm, a method of extending the period of circadian rhythm in a subject, said method comprising administering to said subject an inhibitor of adenylyl cyclase, and to adenylyl cyclase inhibitor for use in the treatment of a disorder of the circadian rhythm. Preferably the inhibitor is a P-site inhibitor, preferably 9-(tetrahydrofuryl)-adenine. The composition may further comprise a JNK inhibitor.

Abstract: The present invention is directed to aryl sulfamide derivatives of formula I: or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic neuropathy, pain, and other diseases or disorders.

Abstract: Atorvastatin lactone is prepared by hydrogenating tert-butyl isopropylidene nitrile to tert-butyl isopropylidene amine and condensing the amine with the diketone of atorvastatin to form acetonide ester. The diol protecting acetonide ester is deprotected to form a diol ester by dissolving the acetonide ester in methanol and treating with an acid. The diol ester is saponified to form a sodium salt. Methanol is removed from the reaction mixture by distillation. The sodium salt is reacidified to the free diol acid and atorvastatin lactone is formed from the diol acid. The atorvastatin lactone is directly dried without further purification.

Abstract: An orthopoxvirus vector, such as vaccinia, is described in which the A46R protein from vaccinia, or a closely related protein from any orthopoxvirus is not expressed or is expressed but is non-functional. Also described is the use of a vaccinia virus A46R protein or a closely related protein from any orthopoxvirus, or a functional peptide, peptidometic, fragment or derivative thereof, or a DNA vector expressing any of the above in the modulation and/or inhibition of IL1R/TLR superfamily signalling.

Abstract: An isolated polypeptide comprises an amino acid sequence of SEQ ID No. 1 or 2 or a variant or fragment thereof. The variant may comprise an amino acid sequence that is at least 70% or 95% identical to the amino acid sequence of SEQ ID No. 1 or 2. A fragment thereof may be a peptide comprising at least 12 contiguous amino acids of SEQ ID No. 1 or 2. The polypeptide exhibits toll-like receptor activity. The TLR has been named TLR1 4. TLR receptors recognise a range of ligands and activate a series of signalling pathways that lead to the induction of immune and inflammatory genes.